ACETAZOLAMIDE SODIUM - Generic Drug Details

What are the generic drug sources for acetazolamide sodium and what is the scope of patent protection?

Acetazolamide sodium is the generic ingredient in two branded drugs marketed by Avet Lifesciences, Endo Operations, Hikma, Hospira, Mylan Asi, Xgen Pharms, Zydus Pharms, and Teva Womens, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

Six suppliers are listed for this compound.

Summary for ACETAZOLAMIDE SODIUM

US Patents:	0
Tradenames:	2
Applicants:	8
NDAs:	8
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	9
Patent Applications:	333
What excipients (inactive ingredients) are in ACETAZOLAMIDE SODIUM?	ACETAZOLAMIDE SODIUM excipients list
DailyMed Link:	ACETAZOLAMIDE SODIUM at DailyMed

Recent Clinical Trials for ACETAZOLAMIDE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Diego	Phase 1/Phase 2
The Leona M. and Harry B. Helmsley Charitable Trust	Phase 1/Phase 2
JDRF	Phase 1/Phase 2

See all ACETAZOLAMIDE SODIUM clinical trials

Pharmacology for ACETAZOLAMIDE SODIUM

Drug Class	Carbonic Anhydrase Inhibitor
Mechanism of Action	Carbonic Anhydrase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ACETAZOLAMIDE SODIUM

S01EC	Carbonic anhydrase inhibitors
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for ACETAZOLAMIDE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	ACETAZOLAMIDE SODIUM	acetazolamide sodium	INJECTABLE;INJECTION	040108-001	Oct 30, 1995		DISCN	No	No
Mylan Asi	ACETAZOLAMIDE SODIUM	acetazolamide sodium	INJECTABLE;INJECTION	200880-001	May 9, 2012	AP	RX	No	No
Avet Lifesciences	ACETAZOLAMIDE SODIUM	acetazolamide sodium	INJECTABLE;INJECTION	202693-001	Dec 19, 2014	AP	RX	No	No

ACETAZOLAMIDE SODIUM Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Acetazolamide Sodium

Introduction

Acetazolamide, sold under the trade name Diamox among others, is a versatile medication with a wide range of medical applications, including the treatment of glaucoma, epilepsy, acute mountain sickness, and heart failure. Here, we will delve into the market dynamics and financial trajectory of acetazolamide sodium, exploring its current market size, growth projections, and the factors influencing its demand.

Market Size and Forecast

The acetazolamide market has shown significant growth in recent years. As of 2022, the market size was valued at USD 263.04 billion. It is projected to reach USD 499.69 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.60% from 2023 to 2030[3].

Drivers of Market Growth

Several factors are driving the growth of the acetazolamide market:

Increasing Prevalence of Medical Conditions

The rising prevalence of conditions such as glaucoma, epilepsy, and heart failure is a major driver. Acetazolamide is used to treat these conditions, and as the incidence of these diseases increases, so does the demand for the medication[4].

Expansion of Adventure and Travel Industries

The growth in adventure and travel industries, particularly in high-altitude regions, has increased the demand for acetazolamide as a treatment for acute mountain sickness. This trend is expected to continue, contributing to the market's expansion[3].

Neurological Disorders

Acetazolamide is also prescribed for certain types of seizures and as an adjunct therapy in neurological disorders. The increasing prevalence of these conditions further boosts the demand for the drug[4].

Challenges and Competitors

Despite the positive growth trajectory, the acetazolamide market faces several challenges:

Alternative Medications and Therapies

The availability of alternative medications and therapies for specific conditions can impact the market share of acetazolamide. For instance, other diuretics and treatments may be preferred in certain cases, potentially reducing the demand for acetazolamide[3].

Side Effects and Complications

While acetazolamide is generally safe, it can have serious side effects such as nephrocalcinosis and nephrolithiasis, especially when combined with other treatments like sodium bicarbonate. These risks need to be carefully managed to maintain patient trust and market stability[2].

Medical Uses and Mechanism of Action

Understanding the medical uses and mechanism of action of acetazolamide is crucial for appreciating its market dynamics.

Medical Uses

Acetazolamide is used in various medical conditions, including glaucoma, epilepsy, acute mountain sickness, heart failure, and idiopathic intracranial hypertension. It is also used to alkalinize urine and treat conditions like Ménière's disease and periodic paralysis[4].

Mechanism of Action

As a carbonic anhydrase inhibitor, acetazolamide works by inhibiting the enzyme carbonic anhydrase, which catalyzes the reaction between carbon dioxide and water to form carbonic acid. This inhibition leads to a decrease in the reabsorption of sodium and chloride ions in the kidneys, resulting in increased urine production and a reduction in intraocular pressure[4].

Clinical Applications and Innovations

Recent studies have highlighted innovative uses of acetazolamide:

Heart Failure and Hyponatraemia

Acetazolamide has shown promise as an alternative diuretic to vasopressin antagonists for correcting hyponatraemia in heart failure patients. It enhances free water clearance and has a vasopressin blockade-like effect, making it a valuable option for certain patients[1].

Obesity-Induced Glomerular Hyperfiltration

Research has indicated that acetazolamide can reduce glomerular hyperfiltration in obese non-diabetic subjects by activating tubuloglomerular feedback. This could open new avenues for the treatment of obesity-related kidney diseases[5].

Geographical and Demographical Factors

The demand for acetazolamide varies geographically and demographically:

Regional Demand

The market size and growth rate of acetazolamide can differ significantly across different regions due to variations in disease prevalence, healthcare infrastructure, and regulatory environments[3].

Demographical Trends

The increasing aging population and the rising incidence of chronic diseases in various demographics are expected to drive the demand for acetazolamide in the coming years[3].

Key Takeaways

• The acetazolamide market is projected to grow significantly, reaching USD 499.69 billion by 2030.
• The increasing prevalence of medical conditions such as glaucoma, epilepsy, and heart failure drives market growth.
• The expansion of adventure and travel industries also contributes to the demand for acetazolamide.
• Alternative medications and therapies, as well as potential side effects, are challenges that need to be addressed.
• Innovative clinical applications, such as treating heart failure and obesity-induced glomerular hyperfiltration, are expanding the drug's utility.

FAQs

1. What is the primary mechanism of action of acetazolamide? Acetazolamide works as a carbonic anhydrase inhibitor, inhibiting the enzyme that catalyzes the reaction between carbon dioxide and water to form carbonic acid, leading to decreased sodium and chloride reabsorption in the kidneys[4].

2. What are the main medical uses of acetazolamide? Acetazolamide is used to treat glaucoma, epilepsy, acute mountain sickness, heart failure, idiopathic intracranial hypertension, and other conditions such as Ménière's disease and periodic paralysis[4].

3. How is the acetazolamide market expected to grow? The acetazolamide market is projected to reach USD 499.69 billion by 2030, growing at a CAGR of 4.60% from 2023 to 2030[3].

4. What are the potential side effects of acetazolamide? Serious side effects include nephrocalcinosis and nephrolithiasis, especially when combined with other treatments like sodium bicarbonate[2].

5. Can acetazolamide be used as an alternative diuretic in heart failure patients? Yes, acetazolamide has shown promise as an alternative diuretic to vasopressin antagonists for correcting hyponatraemia in heart failure patients due to its vasopressin blockade-like effect[1].

Cited Sources:

1. Vasopressin antagonist-like effect of acetazolamide in a heart failure patient with hyponatraemia - European Heart Journal - Case Reports[1]
2. Acetazolamide and Sodium Bicarbonate Induced Nephrocalcinosis - JAMA Internal Medicine[2]
3. Acetazolamide Market Size, Share, Trends, Analysis & Forecast - Verified Market Research[3]
4. Acetazolamide - Wikipedia[4]
5. Effect of Acetazolamide on Obesity-Induced Glomerular Hyperfiltration - PLOS ONE[5]